Could a daily supplement keep the common cold at bay?

NCT ID NCT07787130

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This trial tests whether a daily supplement called Immune X can help prevent common colds in healthy adults who often get upper respiratory infections. Over 16 weeks during winter, participants take either Immune X or a placebo and track any cold symptoms. The study compares how many people catch a cold, and how long and severe those colds are, to see if the supplement makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Immune X, a dietary supplement taken as a 500 mg capsule daily
What this could lead to
If effective, Immune X could offer a simple, daily supplement to help healthy adults ward off common colds during winter.
What could go wrong
This is an early-stage trial, and supplements often fail to show clear benefits. Results may not apply to everyone, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women aged 18 to 65 years. * History of at least two upper respiratory tract infections during the previous winter season. * Body mass index between 18 and 30 kg/m². * Generally healthy, as determined by the investigator. * Women of childbearing potential must have a negative pregnancy test and agree to use an effective method of contraception during the study. * Covered by French health insurance. * Able and willing to provide written informed consent. Exclusion Criteria: * Current or recent upper respiratory tract infection or COVID-19 infection within 2 weeks before enrollment. * Acute gastrointestinal infection, including gastroenteritis, within 2 weeks before enrollment. * Use of non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks before enrollment. * Use of systemic antibiotics within 3 months before enrollment. * Receipt of any vaccination within 6 weeks before enrollment. * Surgery requiring general anesthesia within 1 month before enrollment. * History of chronic respiratory disease, including asthma or chronic obstructive pulmonary disease. * Food allergy or chronic/recurrent allergic upper airway conditions requiring regular medical treatment, including moderate to severe allergic rhinitis, hay fever, or chronic rhinosinusitis. * Acute lower respiratory tract infection within 6 months before enrollment or ongoing long COVID. * Immunodeficiency (including HIV infection) or autoimmune disease, except stable hypothyroidism. * Severe or uncontrolled chronic disease, including cancer, significant liver, pancreatic, biliary, or renal disease, inflammatory bowel disease, or cardiovascular disease requiring intensive medical management. * Untreated or inadequately controlled diabetes. * History or current diagnosis of periodontitis. * Current chemotherapy, immunosuppressive therapy, or chronic treatment with corticosteroids or opioids. * Specific diets or major dietary changes within 3 months before enrollment, including high-protein, vegan, low-calorie, or low-FODMAP diets, or participation in a weight-loss program. * Current use of dietary supplements that may affect immune or gut microbiota parameters, or discontinuation of such supplements less than 6 weeks before enrollment. * Current smoking or e-cigarette use, or smoking cessation within 6 months before enrollment. * Current drug or alcohol abuse, or a history of abuse within the previous 12 months. * Regular consumption of more than 2 alcoholic drinks per day and unwillingness to maintain stable drinking habits during the study. * Unwillingness to refrain from using over-the-counter cold remedies, nasal washes or sprays, antihistamines, corticosteroids, or NSAIDs during the study. * More than 8 hours per week of vigorous physical activity or planned major changes in physical activity during the study. * Any condition or circumstance that, in the investigator's judgment, may place the participant at unacceptable risk or interfere with study participation or interpretation of study results. * Current participation in another clinical trial or being in an exclusion period from a previous clinical trial. * Pregnant or breastfeeding. * Persons deprived of liberty, under legal protection, or unable to provide informed consent. * Individuals who have reached the regulatory compensation limit for participation in clinical research.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Common cold are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.